Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 1.6% After Insider Selling

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price traded down 1.6% during mid-day trading on Tuesday after an insider sold shares in the company. The stock traded as low as $6.68 and last traded at $6.76. 882,144 shares traded hands during mid-day trading, a decline of 84% from the average session volume of 5,688,068 shares. The stock had previously closed at $6.87.

Specifically, COO Tina Marriott sold 6,000 shares of the stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of $6.31, for a total value of $37,860.00. Following the completion of the sale, the chief operating officer now owns 521,138 shares in the company, valued at approximately $3,288,380.78. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on RXRX. Jefferies Financial Group lowered their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research note on Tuesday, September 3rd. Needham & Company LLC lowered their price objective on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, September 4th. KeyCorp lowered their price objective on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Finally, Leerink Partners lowered their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Tuesday, September 3rd. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $9.40.

Recursion Pharmaceuticals Trading Down 0.9 %

The firm has a market cap of $1.88 billion, a P/E ratio of -4.12 and a beta of 0.80. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.07 and a current ratio of 6.07. The firm has a fifty day moving average of $6.68 and a 200-day moving average of $7.66.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05). The business had revenue of $14.42 million for the quarter, compared to the consensus estimate of $11.96 million. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The firm’s revenue was up 30.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.38) EPS. Equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current year.

Institutional Trading of Recursion Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Perceptive Advisors LLC acquired a new position in shares of Recursion Pharmaceuticals during the 2nd quarter valued at $5,769,000. Capstone Investment Advisors LLC acquired a new position in shares of Recursion Pharmaceuticals during the 1st quarter valued at $161,000. Benjamin F. Edwards & Company Inc. increased its position in shares of Recursion Pharmaceuticals by 6,439.6% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 169,900 shares of the company’s stock valued at $1,274,000 after purchasing an additional 167,302 shares during the period. Scientech Research LLC acquired a new position in shares of Recursion Pharmaceuticals during the 2nd quarter valued at $1,052,000. Finally, Ghisallo Capital Management LLC acquired a new position in shares of Recursion Pharmaceuticals during the 2nd quarter valued at $8,250,000. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.